Zobrazeno 1 - 10
of 16
pro vyhledávání: '"W. W. Offen"'
Publikováno v:
Alzheimer disease and associated disorders. 11
The therapeutic effects of selective cholinergic replacement using oral xanomeline, an m1/m4 receptor agonist, were assessed in a multicenter study of 343 patients with Alzheimer disease (AD). Patients were randomized to parallel treatment arms (plac
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::c56df22bb865cdcca8823119b9e0b5a6
https://pubmed.ncbi.nlm.nih.gov/9339268
https://pubmed.ncbi.nlm.nih.gov/9339268
Publikováno v:
British journal of clinical practice. Supplement. 76
Two doses of nizatidine (150 mg twice daily and 300 mg at bedtime), an H2-receptor antagonist, were compared with placebo in a 12-week, multicentre, randomised, double-blind, parallel study in 466 patients with endoscopically documented gastro-oesoph
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::6876b327a4d9532f3cc7d22e7da97d14
https://pubmed.ncbi.nlm.nih.gov/7794701
https://pubmed.ncbi.nlm.nih.gov/7794701
Autor:
M L, Cloud, W W, Offen
Publikováno v:
British journal of clinical practice. Supplement. 76
In a randomised, multicentre trial, nizatidine 150 mg or 300 mg or placebo was administered twice daily for 6 weeks to 515 patients with gastro-oesophageal reflux disease (GORD). Antacid tablets were taken as needed for pain. Significantly superior r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::ab27b352e785b08a2d59cadf4a3a33d3
https://pubmed.ncbi.nlm.nih.gov/7794700
https://pubmed.ncbi.nlm.nih.gov/7794700
Publikováno v:
Clinical pharmacology and therapeutics. 52(3)
To determine if 150 mg nizatidine twice daily or 300 mg nizatidine at bedtime are similarly effective and to compare each dose with placebo in healing benign gastric ulcers and relieving peptic ulcer symptoms.This study was a randomized, double-blind
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::8bac445749987f179d702aea9b4a8312
https://pubmed.ncbi.nlm.nih.gov/1526089
https://pubmed.ncbi.nlm.nih.gov/1526089
Autor:
M L, Cloud, W W, Offen
Publikováno v:
Digestive diseases and sciences. 37(6)
In a randomized, multicenter trial, nizatidine 150 mg or 300 mg, or placebo, was administered twice daily for six weeks to 515 patients with gastroesophageal reflux disease (GERD). Gelusil antacid tablets were taken as needed for pain. Significantly
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::c62dc0b53aff1531f4951009444327f9
https://pubmed.ncbi.nlm.nih.gov/1587191
https://pubmed.ncbi.nlm.nih.gov/1587191
Publikováno v:
The American journal of gastroenterology. 86(12)
Two doses of nizatidine (150 mg bid and 300 mg hs), an H2-receptor antagonist, were compared with placebo in a 12-wk, multicenter, randomized, double-blind, parallel study in 466 patients with endoscopically documented gastroesophageal reflux disease
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::5e540fea95c8053f6ad813b039d341cf
https://pubmed.ncbi.nlm.nih.gov/1962618
https://pubmed.ncbi.nlm.nih.gov/1962618
Publikováno v:
Scandinavian Journal of Gastroenterology. 22:79-83
A new H2-receptor antagonist, nizatidine (150 mg h.s.), was compared with placebo as maintenance therapy in a randomized, parallel, double-blind, one-year study of 513 patients with recently healed duodenal ulcer. Endoscopies were performed at 0, 3,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::94c23d67c8298f3c00975f5e65f6c892
https://doi.org/10.3109/00365528709094490
https://doi.org/10.3109/00365528709094490
Autor:
S. Chernish, K. C. Lasseter, Richard F. Bergstrom, J. T. Callaghan, D. W. Schneck, G. Aronoff, B. D. Obermeyer, W. W. Offen, M. P. Knadler, R. E. Crabtree, A. Rubin
Publikováno v:
Scandinavian Journal of Gastroenterology. 22:9-17
In this report, the pharmacokinetic, pharmacodynamic, and hormonal effects of nizatidine are reviewed in healthy volunteers and in patients with renal or hepatic impairment. The absolute oral bioavailability of nizatidine exceeded 90%; the half-life
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::12777973606fae20d77ae404a772ed92
https://doi.org/10.3109/00365528709094480
https://doi.org/10.3109/00365528709094480
Autor:
W. W. Offen, M. R. Goldberg
Publikováno v:
Drugs. 36
Utilising a modified fixed-dose, 4 x 3 factorial design, the antihypertensive effects of all combinations of 4 doses of pinacidil (0, 12.5, 25 and 37.5 mg bid) with 3 doses of hydrochlorothiazide (0, 12.5 and 25 mg bid) were studied in patients with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::00526dbfe185a4ce7dd08aa070772f9e
https://pubmed.ncbi.nlm.nih.gov/3076140
https://pubmed.ncbi.nlm.nih.gov/3076140
Publikováno v:
The American journal of gastroenterology. 84(7)
Nizatidine, a new H2-receptor antagonist for the treatment of duodenal ulcer disease, was compared with cimetidine in an 8-wk, randomized, double-blind, multicenter clinical trial. Patients were randomly allocated to receive either nizatidine 300 mg
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::b80636f6841c2bac2d4bc06707c53960
https://pubmed.ncbi.nlm.nih.gov/2389734
https://pubmed.ncbi.nlm.nih.gov/2389734